What are the roles of metalloproteinases in cartilage and bone damage?

Annals of the Rheumatic Diseases

Volumn 64, Issue SUPPL. 4, 2005, Pages

  Murphy, G ^a,b   Lee, M H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGENASE 3; CYTOKINE; DISINTEGRIN; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; L SELECTIN; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE INHIBITOR; METZINCIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUTROPHIL COLLAGENASE; NITRIC OXIDE; SOMATOMEDIN; SYNDECAN 1; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; ZINC DERIVATIVE;

BONE INJURY; CARTILAGE; CELL INTERACTION; CONFERENCE PAPER; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATORY CELL; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ARTHRITIS; BONE RESORPTION; HUMANS; METALLOPROTEASES; PROTEASE INHIBITORS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 27444448207     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.042465     Document Type: Conference Paper

References (24)

1. Fosang AJ, Stanton H, Little CB, Atley LM. Neoepitopes as biomarkers of cartilage catabolism. Inflamm Res 2003;52:277-82.
2. Poole AR, Nelson F, Dahlberg L, Tchetina E, Kobayashi M, Yasuda T, et al. Proteolysis of the collagen fibril in osteoarthritis. Biochem Soc Symp 2003;70:115-23.
3. Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S, et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004;50:131-41.
4. Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 2003;5:94-103.
5. Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? Arthritis Rheum 2002;46:13-20.
6. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
7. Rao BG. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 2005;11:295-322.
8. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003;4:544-58.
9. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.
10. Clark IM, Parker AE. Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets 2003;7:19-34.
11. Patwari P, Gao G, Lee JH, Grodzinsky AJ, Sandy JD. Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage. Osteoarthritis Cartilage 2005;13:269-77.
12. Dickinson SC, Vankemmelbeke MN, Buttle DJ, Rosenberg K, Heinegard D, Hollander AP. Cleavage of cartilage oligomeric matrix protein (thrombospondin-5) by matrix metalloproteinases and a disintegrin and metalloproteinase with thrombospondin motifs. Matrix Biol 2003;22:267-78.
13. Flannery CR, Little CB, Caterson B, Hughes CE. Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (MMPs) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes. Matrix Biol 1999;18:225-37.
14. Andersen TL, del Carmen Ovejero M, Kirkegaard T, Lenhard T, Foged NT, Delaisse JM. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence or MMPs synthesized by other cells. Bone 2004;35:1107-19.
15. Verrier S, Hogan A, McKie N, Horton M. ADAM gene expression and regulation during human osteoclast formation. Bone 2004;35:34-46.
16. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004;16:558-64.
17. Mohammed FF, Smookler DS, Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis 2003;62(suppl 2):ii43-ii7.
18. Garnero P, Mazieres B, Gueguen A, Abbal M, Berdah L, Lequesne M, et al. Cross-sectional association or 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol 2005;32:697-703.
19. Baker AH, Kritz A, Work LM, Nicklin SA. Cell-selective viral gene delivery vectors for the vasculature. Exp Physiol 2005;90:27-31.
20. Lee MH, Rapti M, Murphy G. Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: Fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-α-converting enzyme. J Biol Chem 2005;280:15967-75.
21. van der Laan WH, Quax PH, Seemayer CA, Huisman LG, Pieterman EJ, Grimbergen JM, et al. Cartilage degradation and invasion by rheumatoid synovial ribroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther 2003;10:234-42.
22. Vincenti MP, Brinckerhoff CE. The potential of signal transduction inhibitors for the treatment of arthritis: Is it all just JNK? J Clin Invest 2001;108:181-3.
23. Mix KS, Sporn MB, Brinckerhoff CE, Eyre D, Schurman DJ. Novel inhibitors of matrix metalloproteinase gene expression as potential therapies for arthritis. Clin Orthop Relat Res 2004;427(suppl):S129-S137.
24. Voils SA, Evans ME, Lane MT, Schosser RH, Rapp RP. Use of macrolides and tetracyclines for chronic inflammatory diseases. Ann Pharmacother 2005;39:86-94.